Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edmund Pezalla

Costa Mesa, CA Medical Doctor

CMS profile 1379462

3515 Harbor Blvd, Costa Mesa, CA 92626

Open in the dashboard

General payments

$606,031

257 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edmund Pezalla of Costa Mesa, CA is reported in the CMS Open Payments database as having received $606,031 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142,859 23
2024 General $51,987 28
2023 General $158,731 66
2022 General $98,841 49
2021 General $42,802 21
2020 General $46,304 21
2019 General $64,507 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edmund Pezalla
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Edmund Pezalla were reported at $142,859. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Edmund Pezalla California median Middle half National median
2019 $64,507 $161 $50–$652 $163
2020 $46,304 $114 $34–$392 $114
2021 $42,802 $137 $41–$509 $132
2022 $98,841 $152 $48–$573 $149
2023 $158,731 $162 $50–$581 $160
2024 $51,987 $162 $52–$583 $164
2025 $142,859 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $130,038 19 payments
  2. Pfizer Inc. $85,756 28 payments
  3. Regeneron Pharmaceuticals, Inc. $70,478 1 payment
  4. Bayer HealthCare Pharmaceuticals Inc. $52,394 46 payments
  5. Eli Lilly and Company $50,350 13 payments
  6. Genzyme Corporation $41,258 18 payments
  7. Regeneron Healthcare Solutions, Inc. $34,085 43 payments
  8. Sanofi Pasteur Inc. $13,249 6 payments
  9. Novo Nordisk AS $12,750 5 payments
  10. EMD Serono, Inc. $10,713 5 payments
  11. Other $104,960 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $495,778 116 payments
  2. Travel and Lodging $60,811 58 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,153 16 payments
  4. Honoraria $15,705 8 payments
  5. Food and Beverage $3,532 57 payments
  6. Education $52 2 payments
Products named General payments · program years 2019–2025
  1. Nubeqa $40,165 35 payments
  2. DUPIXENT Immunology $34,351 14 payments
  3. DUPIXENT Inflammation And Immunology $34,085 43 payments
  4. Hizentra $27,600 2 payments
  5. Bavencio $10,563 4 payments
  6. Xolair $7,991 7 payments
  7. VABYSMO $6,481 4 payments
  8. ENTYVIO $6,045 1 payment
  9. IMBRUVICA $6,012 9 payments
  10. Ponvory $5,000 2 payments
  11. Other $26,775 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record